The gastrointestinal stromal tumor (GIST) pipeline will rise with various collaborations and R&D investments. Hereditary risk and genetic factors play an important role in the development of gastrointestinal stromal tumor. Increasing family history of the disease and genetic factors associated with gastrointestinal stromal tumor and low penetration in the market are contributing towards the development of the pipeline. Additionally, increasing awareness regarding various health issues among people is another major factor fueling the pipeline growth for gastrointestinal stromal tumor. According to American Cancer Society, every year around 4,000 to 5,000 people suffer from gastrointestinal stromal tumor in the U.S. Gastrointestinal stromal tumors occur mostly in older adults with age more than 50 years. It affects women and men equally.
Gastrointestinal stromal tumorsis rare form of tumor which is found in gastrointestinal tract or digestive tract. It mostly occurs on the walls of stomach, varying from benign to malignant. The symptoms of gastrointestinal stromal tumors include pain or discomfort in the stomach, blood in vomit or stools, fatigue, sickness and anaemia. But in the early stages of the disease symptoms does not occur resulting in late diagnosis of the tumor. The diagnosis of Gastrointestinal stromal tumors is done by conducting endoscopy, magnetic resonance imaging (MRI) and computed tomography (CT) scan. The treatment of gastrointestinal stromal tumors include surgery and biological therapies. Surgery is the most common treatment for gastrointestinal stromal tumors and it is chosen by analysing the location of the tumor and the size of the tumor. Biological therapies include treatment with drugs including Imatinib (Glivec), Sunitinib (Sutent) and Regorafenib (Stivarga).
Arog Pharmaceuticals, Inc. is in the process of developing a drug by the name Crenolanib for the treatment of gastrointestinal stromal tumors. Crenolanib is a small molecule that inhibits Fms-like tyrosine kinase 3 ligand (FLT3L), which is in the Phase III stage of development. Boston Biomedical, Inc. is currently involved in the process of developing BBI503, which is in Phase II stage of clinical trial. The drug candidate is a small molecule that acts as an inhibitor of stemness proteins. Plexxikon, Inc. is developing PLX9486 for the treatment of gastrointestinal stromal tumors. It is currently in Phase I/II stage of development and acts as a small molecule that inhibits proto oncogene protein c-kit. Plexxikon, Inc. is also in the process of developing another drug by the name of PLX3397, which is in Phase I/II stage of development. It is a small molecule and inhibits proto oncogene protein c-kit. Blueprint Medicines Corporation is in the process of developing BLU 285 which is a small molecule and acts as a proto oncogene protein c-kit inhibitor. DCC-2618 is being developed by Deciphera Pharmaceuticals LLC for the treatment of gastrointestinal stromal tumors. It is in Phase I stage of development inhibiting proto oncogene protein c-kit.
Some of the companies having a pipeline of gastrointestinal stromal tumors therapeutics include Chipscreen Biosciences Ltd., GlaxoSmithKline plc, Pfizer, Boston Biomedical, Inc., Bayer AG, Immunicum AB, Plexxikon, Inc., Blueprint Medicines Corporation, Array BioPharma Inc., ArQule, Inc., Arog Pharmaceuticals, Inc., Merck Sharp & Dohme Corp., Deciphera Pharmaceuticals LLC.